Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2010 Jan 21;30(4):758–765. doi: 10.1161/ATVBAHA.109.199893

Figure 1. The effect of eNOS inhibitor, L-NAME, on palmitate-mediated endothelial inflammation and insulin signaling.

Figure 1

HMEC were treated with vehicle or the eNOS inhibitor (L-NAME) 50 µM 3 h and then treated with BSA (C) or BSA-palmitate (F) (10 µM) for 3 h, followed by insulin stimulation (I) (100 nM, 15 min). Cell lysates were analyzed by Western blot and fold increase over vehicle, BSA control group was calculated for each experiment (n=3) A. Fold increase of phospho-IκBα protein normalized to GAPDH levels. B. Fold increase of ICAM protein levels normalized to GAPDH levels. C. Fold increase in IRS-1 tyrosine phosphorylation normalized to total IRS-1. D. Fold increase in pAkt normalized to total Akt E. Fold increase in peNOS normalized to total eNOS levels. *p<0.05